Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study
A comprehensive seasonal infant immunisation program using nirsevimab, such as the one implemented in WA, can greatly reduce the RSV-hospitalisation burden in young children, with immunisation at birth prior to and during the yearly epidemic having the most impact on hospitalisations.
Authors
- Cara Minney–Smith (ORCID: https://orcid.org/0000-0003-4445-826X)
- Hannah C. Moore (ORCID: https://orcid.org/0000-0001-6434-8290)
- Fiona Giannini (ORCID: https://orcid.org/0000-0001-6302-506X)
- Peter Richmond (ORCID: https://orcid.org/0000-0001-5796-735X)
- Huong Le (ORCID: https://orcid.org/0000-0003-4630-5734)
- Christopher C. Blyth (ORCID: https://orcid.org/0000-0003-2017-0683)
- Kathryn Glass (ORCID: https://orcid.org/0000-0001-5905-1310)
- Alexandra B. Hogan (ORCID: https://orcid.org/0000-0002-6271-9921)
- Ewan R. Cameron (ORCID: https://orcid.org/0000-0001-8311-1491)
Institutions
- Australian National University (AU)
- New South Wales Department of Health (AU)
- The University of Western Australia (AU)
- Princess Margaret Hospital for Children (AU)
- Queen Elizabeth II Medical Centre (AU)
- Sydney Local Health District (AU)
- Pathwest Laboratory Medicine (AU)
Publication Details
- Journal
- Vaccine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127155
- Citations
- 3
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Stan Perron Charitable Foundation